Total Payments
$1,655
2024 Payments
$374.65
Companies
7
Transactions
99
Medicare Patients
9,290
Medicare Billing
$1.2M
Payment Breakdown by Category
Food & Beverage$1,456 (88.0%)
Education$198.95 (12.0%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $1,456 | 97 | 88.0% |
| Education | $198.95 | 2 | 12.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Gilead Sciences, Inc. | $953.94 | 78 | $0 (2024) |
| Janssen Products, LP | $318.11 | 3 | $0 (2019) |
| Merck Sharp & Dohme LLC | $162.57 | 10 | $0 (2024) |
| Janssen Biotech, Inc. | $120.68 | 4 | $0 (2019) |
| ViiV Healthcare Company | $57.67 | 2 | $0 (2024) |
| Mylan Institutional Inc. | $21.55 | 1 | $0 (2019) |
| Janssen Pharmaceuticals, Inc | $20.00 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $374.65 | 26 | Gilead Sciences, Inc. ($257.30) |
| 2023 | $219.45 | 13 | Gilead Sciences, Inc. ($144.01) |
| 2022 | $156.31 | 11 | Gilead Sciences, Inc. ($156.31) |
| 2021 | $169.82 | 14 | Gilead Sciences, Inc. ($169.82) |
| 2020 | $74.30 | 4 | Gilead Sciences, Inc. ($74.30) |
| 2019 | $310.37 | 24 | Gilead Sciences, Inc. ($136.01) |
| 2018 | $192.95 | 4 | Janssen Products, LP ($119.16) |
| 2017 | $156.67 | 3 | Janssen Products, LP ($99.00) |
All Payment Transactions
99 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/13/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $32.56 | General |
| 12/10/2024 | Merck Sharp & Dohme LLC | DIFICID (Drug), ZERBAXA | Food and Beverage | In-kind items and services | $16.29 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 12/09/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $12.63 | General |
| 11/26/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $11.63 | General |
| 11/12/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $8.53 | General |
| 11/08/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $2.62 | General |
| 10/19/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $34.61 | General |
| 10/15/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $8.92 | General |
| 10/02/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $10.78 | General |
| 09/18/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $7.28 | General |
| 09/17/2024 | Merck Sharp & Dohme LLC | DIFICID (Drug), ZERBAXA | Food and Beverage | In-kind items and services | $17.49 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 09/16/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $2.68 | General |
| 08/22/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $3.42 | General |
| 08/20/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $2.52 | General |
| 08/07/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $32.99 | General |
| 07/09/2024 | Merck Sharp & Dohme LLC | DIFICID (Drug), ZERBAXA | Food and Beverage | In-kind items and services | $19.09 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 06/24/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $15.92 | General |
| 05/16/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $10.25 | General |
| 05/16/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $4.36 | General |
| 05/13/2024 | Merck Sharp & Dohme LLC | DIFICID (Drug), ZERBAXA | Food and Beverage | In-kind items and services | $18.23 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 04/15/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $16.45 | General |
| 03/21/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $10.01 | General |
| 03/06/2024 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $28.02 | General |
| Category: HIV | ||||||
| 03/05/2024 | Merck Sharp & Dohme LLC | DIFICID (Drug), RECARBRIO, ZERBAXA | Food and Beverage | In-kind items and services | $18.23 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 02/23/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $21.57 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 17 | 2,250 | 3,601 | $528,358 | $281,791 |
| 2022 | 17 | 2,299 | 3,928 | $573,110 | $300,052 |
| 2021 | 18 | 2,384 | 4,104 | $609,253 | $328,287 |
| 2020 | 16 | 2,357 | 3,800 | $557,074 | $294,350 |
Total Patients
9,290
Total Services
15,433
Medicare Billing
$1.2M
Procedure Codes
72
All Medicare Procedures & Services
72 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 618 | 1,688 | $203,117 | $117,350 | 57.8% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 450 | 483 | $110,163 | $55,182 | 50.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 247 | 372 | $59,282 | $28,874 | 48.7% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 125 | 125 | $28,735 | $18,276 | 63.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 94 | 107 | $24,116 | $11,894 | 49.3% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 187 | 236 | $23,347 | $11,893 | 50.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 66 | 98 | $22,087 | $8,400 | 38.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 66 | 66 | $19,205 | $7,748 | 40.3% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 43 | 60 | $10,372 | $6,272 | 60.5% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 35 | 35 | $6,864 | $3,459 | 50.4% |
| G0444 | Annual depression screening, 5 to 15 minutes | Office | 2023 | 119 | 119 | $3,958 | $2,551 | 64.5% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 46 | 52 | $3,332 | $2,233 | 67.0% |
| 99441 | Telephone medical discussion with physician, 5-10 minutes | Office | 2023 | 33 | 36 | $3,561 | $1,738 | 48.8% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 43 | 43 | $1,935 | $1,489 | 77.0% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2023 | 16 | 19 | $3,041 | $1,478 | 48.6% |
| 99202 | New patient office or other outpatient visit, 15-29 minutes | Office | 2023 | 19 | 19 | $2,443 | $1,256 | 51.4% |
| 90694 | Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage | Office | 2023 | 14 | 14 | $1,785 | $1,061 | 59.5% |
| 90686 | Influenza vaccine, quadrivalent, preservative free, 0.5 ml dosage | Office | 2023 | 29 | 29 | $1,015 | $635.10 | 62.6% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 631 | 1,977 | $237,892 | $126,543 | 53.2% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 381 | 411 | $93,741 | $49,967 | 53.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 301 | 434 | $69,162 | $35,183 | 50.9% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2022 | 130 | 130 | $29,884 | $19,758 | 66.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 128 | 164 | $36,962 | $17,578 | 47.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 83 | 107 | $24,116 | $9,506 | 39.4% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 88 | 93 | $16,076 | $8,602 | 53.5% |
About Dr. John Mcneil, M.D
Dr. John Mcneil, M.D is a Infectious Disease healthcare provider based in Silver Spring, Maryland. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/06/2006. The National Provider Identifier (NPI) number assigned to this provider is 1407828254.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. John Mcneil, M.D has received a total of $1,655 in payments from pharmaceutical and medical device companies, with $374.65 received in 2024. These payments were reported across 99 transactions from 7 companies. The most common payment nature is "Food and Beverage" ($1,456).
As a Medicare-enrolled provider, Mcneil has provided services to 9,290 Medicare beneficiaries, totaling 15,433 services with total Medicare billing of $1.2M. Data is available for 4 years (2020–2023), covering 72 distinct procedure/service records.
Ad
Practice Information
- Specialty Infectious Disease
- Location Silver Spring, MD
- Active Since 02/06/2006
- Last Updated 09/30/2011
- Taxonomy Code 207RI0200X
- Entity Type Individual
- NPI Number 1407828254
Products in Payments
- PREZCOBIX (Drug) $291.87
- Symtuza (Drug) $146.92
- DIFICID (Drug) $119.05
- CABENUVA (Biological) $29.65
- DOVATO (Drug) $28.02
- ISENTRESS (Drug) $27.45
- Cimduo (Drug) $21.55
- XARELTO (Drug) $20.00
- ZERBAXA (Drug) $16.07
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Infectious Disease Doctors in Silver Spring
Dr. Phuong Trinh
Infectious Disease — Payments: $220,875
Infectious Disease $220,875
Michael Koren, M.d, M.D
Infectious Disease — Payments: $106,100
Infectious Disease $106,100
Dr. Lynette Posorske, Md, MD
Infectious Disease — Payments: $79,479
Infectious Disease $79,479
Barbara Matthews, Md, Mph, MD, MPH
Infectious Disease — Payments: $36,685
Infectious Disease $36,685
Mrs. Rebecca Shaffer, Md, MD
Infectious Disease — Payments: $9,143
Infectious Disease $9,143
Vasilios Pyrgos, Md, MD
Infectious Disease — Payments: $7,622
Infectious Disease $7,622